Can N-terminal pro-B natriuretic peptide (NT-ProBNP) levels identify individuals at higher cardiovascular risk, independent of their blood glucose levels?
NT-proBNP Cardiac Test, a survey study in 5502 participants (Cardiovasc Diabetol 2022, PMID 36344968) — after a median follow-up of 13 years, 1509 participants died, with 330 deaths due to cardiovascular causes. The study design does not evaluate whether intensification of treatment based on biomarker data might lead to improvements in cardiovascular risk reduction.
Source: Cardiovasc Diabetol 2022, PMID 36344968 ↗ · Research map · How Magellan grades evidence · evidence confidence: high
Cardiovasc Diabetol · 2022 · PMID 36344968 · DOI 10.1186/s12933-022-01671-w
Higher NT-ProBNP levels are independently linked to increased risk of death from any cause and cardiovascular disease, regardless of blood sugar levels.
The question
Can N-terminal pro-B natriuretic peptide (NT-ProBNP) levels identify individuals at higher cardiovascular risk, independent of their blood glucose levels?
What they tested
The study aims to evaluate if NT-ProBNP can help identify subjects at higher cardiovascular risk, independently of blood glucose levels.
How they did it
Serum NT-ProBNP levels were measured in 5502 participants aged 45-79 years without heart failure from the 1999-2004 National Health and Nutrition Examination Survey. Participants included 3380 with normoglycemia, 1125 with pre-diabetes, and 997 with diabetes. Cox and Fine Gray models, adjusted for cardiovascular risk factors, were used to assess the association between NT-ProBNP levels and all-cause and cardiovascular mortality through December 2015.
What they found
After a median follow-up of 13 years, 1509 participants died, with 330 deaths due to cardiovascular causes. Compared to participants with NT-ProBNP < 100 pg/ml, those with levels 100-300 pg/ml had a higher incidence of all-cause mortality (HR 1.61) and cardiovascular mortality (HR 1.57). Participants with NT-ProBNP levels ">=" 300 pg/ml had an even higher incidence of all-cause mortality (HR 2.96) and cardiovascular mortality (HR 2.08). This association remained consistent across subgroups based on glycemic status, obesity, age, and sex.
| All-cause mortality (100-300 pg/ml) | 1.61 | |
|---|---|---|
| All-cause mortality (">=" 300 pg/ml) | 2.96 | |
| Cardiovascular mortality (100-300 pg/ml) | 1.57 | |
| Cardiovascular mortality (">=" 300 pg/ml) | 2.08 |
Hazard Ratios for all-cause and cardiovascular mortality compared to participants with NT-ProBNP < 100 pg/ml.
What it means
Elevated NT-ProBNP is independently associated with all-cause and cardiovascular mortality in the general population and may help identify patients at the highest risk.
Limitations
The study design does not evaluate whether intensification of treatment based on biomarker data might lead to improvements in cardiovascular risk reduction.
The paper at a glance
| Title | NT-proBNP and mortality across the spectrum of glucose tolerance in the general US population |
|---|---|
| Journal | Cardiovasc Diabetol |
| Year | 2022 |
| PMID | 36344968 ↗ |
| DOI | 10.1186/s12933-022-01671-w ↗ |
| Topic | Cardiovascular & vascular aging |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
NT-proBNP Cardiac Test
Improves cardiovascular risk estimation. Research relevant to this mechanism is indexed on PubMed and linked below; it describes the mechanism rather than this specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). Can N-terminal pro-B natriuretic peptide (NT-ProBNP) levels identify individuals at higher cardiovascular risk, independent of their blood glucose levels? [Plain-English summary of Cardiovasc Diabetol 2022, PMID 36344968, DOI 10.1186/s12933-022-01671-w]. Magellan Longevity. https://magellanlongevity.com/study/d36344968.html@misc{magellan_d36344968,
title = {Can N-terminal pro-B natriuretic peptide (NT-ProBNP) levels identify individuals at higher cardiovascular risk, independent of their blood glucose levels?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/d36344968.html}},
note = {Plain-English summary of PubMed PMID 36344968; DOI 10.1186/s12933-022-01671-w; Cardiovasc Diabetol 2022. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/d36344968.htmlRelated studies in the Magellan library
- Preoperative NT-proBNP and Cardiovascular Events After Noncardiac Surgery: A Cohort StudyAnn Intern Med · 2019 · PMID 31869834
- What are the updated Canadian Cardiovascular Society guidelines for perioperative cardiac risk…Can J Cardiol · 2016 · PMID 27865641
- Continuous Glucose Monitoring and Physical ActivityInternational Journal of Environmental Research and Public Health · 2022 · PMID 36231598
- Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose…J Clin Endocrinol Metab · 2022 · PMID 35094087
- Astaxanthin supplementation impact on insulin resistance, lipid profile, blood pressure, and…Phytother Res · 2023 · PMID 37874168
- Prebiotic Inulin Supplementation and Peripheral Insulin Sensitivity in adults at Elevated Risk…Nutrients · 2021 · PMID 34579112
All 67 Magellan summaries on cardiovascular & vascular aging →
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →